Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Evanson Jeff there OTLK shares were sold to cover Taxes.
After the sale, he have 745.975 OTLK Shares.
(See SEC Form 4 January 19, 2023)
OTLK - Strengthens Medical Affairs and Commercial Expertise with Appointments of Surendra Sharma, MD, Senior Vice President of Medical Affairs and Glen Olsheim, Executive Director of Commercial Excellence
See more information about OTLK at https://www.reddit.com/r/OTLK_Investors/
$OTLK - My Thoughts Regarding the Conversion of the $31 Million Loan into OTLK Shares and Its Impact on the OTLK-Buyout Date
If the buyer in the OTLK-Buyout does not want Streeterville to convert the $31.8 Million loan into OTLK shares, he will have to announce the Buyout in January 2023 for this to be completed by March 30, 2023.
The Conversion can take place from April 01, 2023 if the daily volume weighted average price of the OTLK Common Stock on Nasdaq equals or exceeds $2.50 per share for a period of 30 consecutive trading days.
If this happens Streeterville has the right to convert all or any portion of the outstanding balance under the Note into shares of Common Stock at a conversion price of $2.00 per share.
OTLK - $25 Million Registered Direct Offering
I want to see if BMS or ABC they will buy some OTLK shares on that $25 Million offering (they can be a "Accredited Investors").
If BMS buy some OTLK shares on that Offering is a Strong signal for a Buyout, and they are the buyer.
Buyout must be before Streeterville can do the convertible promissory note on OTLK shares after April 1, 2023.
If this append the Buyer will pay in full that loan to Streeterville.
OTLK FDA Marker Approval of ONS-5010, there PDUFA is target for August 29, 2023
BTIG Initiates Coverage On Outlook Therapeutics with Buy Rating, Announces Price Target of $7
Benzinga · 10/31/2022 08:18
BTIG analyst Julian Harrison initiates coverage on Outlook Therapeutics (NASDAQ:OTLK) with a Buy rating and announces Price Target of $7.
OTLK Today we had 3 very good news from the FDA:
1) Acceptance of the OTLK BLA.
2) The FDA set a Prescription Drug User Fee Act (PDUFA) goal date of August 29, 2023.
3) ONS-5010, if approved, is expected to receive 12 years of regulatory exclusivity in the United States.
With all of this and also the Approval of the OTLK accounts for the fiscal year 2022 (as of Sep 30, 2022), the buyout to OTLK should be announced.
OTLK - Conference Panel
Jeff Evanson, Chief Commercial Officer, will moderate a panel today at the #OMIF2022 in Irvine, CA to discuss working with payors, physicians and hospitals on best practices for innovative payment incentives and processes.
SOURCE:
OTLK on TWITTER
OTLK - Outlook Therapeutics says AmerisourceBergen agreement puts it on an equal footing for market access.
President and CEO Russ Trenary and Senior Vice President of Commercial Operations Joel Prieve join Proactive's Stephen Gunnion with details of a strategic relationship with healthcare company AmerisourceBergen.
OTLK - Enough money until FDA approval and market launch of ONS-5010.
I was surprised that the commercialization agreement between OTLK and AmerisourceBergen did not include the payment of an initial fee to OTLK for the exclusive commercialization of ONS-5010 bevacizumab in the USA by AmerisourceBergen.
I think that instead of OTLK receiving an initial fee, AmerisourceBergen will pay the launch costs of the ONS-5010 OTLK product.
If this happens like this, OTLK will have enough money until FDA approval and market launch of ONS-5010.
See on Slide 29 October 4, 2022 Corporate Presentation:
"Leveraging strategic commercialization agreement with AmerisourceBergen to preserve capital and enhance commercial reach"
Because OTLK will not need to spend money to launch the product on the market, OTLK decided to pay off the last loan in advance in full.
I don't think there will be any further dilution in OTLK, because a buyout is on the way. Let's see if I'm thinking right!
OTLK - CORPORATE PRESENTATION OCTOBER 4, 2022
New Information on Slides:
SLIDE 5 (Strategic commercialization agreement with AmerisourceBergen)
SLIDE 17 (Commercial Expansion AmerisourceBergen ? Establish commercial team distribution partners/network (Done)
SLIDE 18 New Slide (Strategic Commercialization Partnership in U.S. with Preeminent Leader in Specialty Pharma Distribution)
SLIDE 19 New Information (Compelling Clinical Data Support Potential FDA Approval in Wet AMD)
SLIDE 28 New Information Market Cap and Average Volume
SLIDE 29 New Information (Leveraging strategic commercialization agreement with AmerisourceBergen to preserve capital and enhance commercial reach)
SOURCE:
https://ir.outlooktherapeutics.com/static-files/b4d4e6f0-8b5d-44dc-b52a-7345e7eb33cc
Outlook Therapeutics® to Present at Eyecelerator @ AAO 2022
As part of the event, Russ Trenary, President and Chief Executive Officer will present as a part of the Retina Showcase, and Terry Dagnon, Chief Operations Officer will participate in a panel presentation. Details for the presentations are as follows:
Panel: Defining Clinically Relevant Endpoints in Approval Trials
Time: 11:45 AM – 12:30 PM ET
Discussion Topic: Government, academic, and industry experts offer perspectives on benchmarking practices that accurately characterize the effectiveness of treatments in clinical studies and meet regulatory requirements.
Company Participant: Terry Dagnon, Chief Operations Officer
Company Presentation: Retina Showcases
Time: 2:46 PM – 2:51 PM ET
Presenter: Russ Trenary, President and Chief Executive Officer
SOURCE:
https://ir.outlooktherapeutics.com/node/10616/pdf
OTLK - Outlook Therapeutics® and AmerisourceBergen Announce Strategic Commercialization Agreement for ONS-5010 for the Treatment of Wet AMD
AmerisourceBergen will provide third-party logistics (3PL) services and distribution, as well as medical information and pharmacovigilance services in the United States.
AmerisourceBergen’s commercialization support will expand to include additional services, such as patient services and field solutions.
A relationship with AmerisourceBergen for ONS-5010 is a critical step in the next phase of our pre-commercial strategy execution,” commented C. Russell Trenary, III, President and CEO of Outlook Therapeutics.
OTLK working with AmerisourceBergen will help to provide Outlook Therapeutics with an accelerated pathway to deliver a high-quality customer experience to retina specialists.
Outlook Therapeutics is also exploring a relationship with AmerisourceBergen to support the launch of ONS-5010 in international markets.
AmerisourceBergen expanded its global distribution capabilities in 2021 with the acquisition of Alliance Healthcare, a leading wholesaler of healthcare products in Europe.
SOURCE:
https://ir.outlooktherapeutics.com/node/10626/pdf
OTLK - UPDATE: Chardan Capital analyst Daniil Gataulin initiates coverage on Outlook Therapeutics (NASDAQ:OTLK) with a Buy rating and announces Price Target of $10
Benzinga · 09/13/2022 06:06
SOURCE:
https://www.webull.com/news/7297859645928448
$OTLK - The Outlook Therapeutics team will be attending the 22nd #Euretina Congress, September 1-4, in Hamburg, Germany.
See more information about OTLK at reddit.com/r/OTLK_Investors/
OTLK - The Outlook Therapeutics team will be attending ASRS (American Society of Retina Specialists), July 13-16, in New York City.
For more information on $OTLK's ONS-5010 ophthalmic bevacizumab, visit https://outlooktherapeutics.com
#ASRS2022
@asrsdocs
https://www.reddit.com/r/OTLK_Investors/
OTLK - CORPORATE PRESENTATIONS JULY 05, 2022
Good News:
U.S. FDA BLA submission targeted September 2022 with anticipated approval to follow 8-12 months later.
Sufficient capital for pre-launch activities and potentially through launch.
SOURCE:
https://ir.outlooktherapeutics.com/static-files/65b18fdb-77dd-4afb-8401-1169d0f9a743
OTLK - Outlook Therapeutics Announces Full Cash Pre-Payment of Convertible Promissory Note
July 5, 2022 ISELIN, N.J., July 05, 2022
(GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, announced today the full cash pre-payment of its unsecured convertible promissory note dated November 4, 2020, as amended November 16, 2021 (the “Note”).
All obligations under the Note have been repaid in cash and satisfied.
OTLK - Trenary C Russell III + Dagnon Terry they Bought OTLK Shares on June 21, 2022
TRENARY C RUSSELL III Bought 19,925 shares at $1.06 on June 21, 2022.
DAGNON TERRY Bought 10,000 shares at $1.05 on June 21, 2022.
(See more information about OTLK at r/OTLK_Investors)
SOURCE:
https://ir.outlooktherapeutics.com/static-files/64f27997-0f1c-4ce0-b050-9e7707370f17
https://ir.outlooktherapeutics.com/static-files/22b8fc54-60ef-49c4-a619-e8a2f6ef12eb
OTLK - Corporate Presentation JUNE 2022
New on Slide 05
• Compelling pivotal data support U.S. FDA BLA submission targeted Sept. 2022
• Launch anticipated Q4 2023, if approved.
New on Slide 27
• Sufficient capital to support pre-launch activities for ONS-5010 and a pathway to potentially support launch if approved.
New on Slide 28
• U.S. FDA BLA submission targeted September 2022 with anticipated approval to follow 8-12 months later.
• Sufficient capital for pre-launch activities and potentially through launch.
(in May they said **"**Sufficient capital through the anticipated approval of the ONS-5010 BLA")
OTLK Did not give any explanation why they withdraw the BLA!
They only said they are "Compelling pivotal data support U.S. FDA BLA submission target Sept. 2022"
( See more information about OTLK at r/OTLK_Investors )
SOURCE:
https://ir.outlooktherapeutics.com/static-files/10b909de-a80a-45af-a98d-470ce9f068ef
OTLK - HOLDING STRONG
I hope OTLK investors learn from these wise words from Great Investors who made huge fortunes on the stock market We need to Remember there words:
WARREN BUFFETT Quotes:
1) “The stock market is a device for transferring money from the impatient to the patient.”
2) “Time is the friend of the wonderful business, the enemy of the mediocre.”
3) "Short-term price fluctuations do not affect the long-term value."
4) "If you can control your emotions, you can control your money".
CHARLIE MUNG Quote:
"THE BIG MONEY IS NOT IN THE BUYING AND THE SELLING, BUT IN THE WAITING."
More information about OTLK at r/OTLK_Investors
As of today, OTLK BLA Acceptance by FDA can take place on any day.
If you want buy more OTLK Shares is better to do now, so you won't regret it later!
PDUFA date expected to be announced in June 2022
Source:
https://ir.outlooktherapeutics.com/static-files/3cdc129d-40e0-4c68-a436-f94352c65d12
OTLK - Corporate Presentation MAY 2022
Good News all as planned
U.S. FDA BLA submitted March 2022 with anticipated approval to follow 9-12 months later.
Sufficient capital through the anticipated approval of the ONS-5010 BLA.
SOURCE:
https://ir.outlooktherapeutics.com/static-files/7590f061-6751-4f3e-89a3-c2101f211735
OTLK - Corporate Presentation MAY 2022
Good News all as planned
U.S. FDA BLA submitted March 2022 with anticipated approval to follow 9-12 months later.
Sufficient capital through the anticipated approval of the ONS-5010 BLA.
SOURCE:
https://ir.outlooktherapeutics.com/static-files/7590f061-6751-4f3e-89a3-c2101f211735
OTLK - Corporate Presentation MAY 2022
Good News all as planned
U.S. FDA BLA submitted March 2022 with anticipated approval to follow 9-12 months later.
Sufficient capital through the anticipated approval of the ONS-5010 BLA.
SOURCE:
https://ir.outlooktherapeutics.com/static-files/7590f061-6751-4f3e-89a3-c2101f211735
OTLK - They Started to Build the Sales Team
Executive Director, Provider Market Access
Job ID 2022-1788 Job Locations US-Remoted
Executive Director, Payer Market Access
Job ID 2022-1787 Job Locations US-Remote
Senior Vice President, Sales
Job ID 2022-1784 Job Locations US-Remote
(See more information about OTLK at r/OTLK_Investors)
Outlook Therapeutics is a late clinical-stage biopharmaceutical company working to develop and launch ONS-5010 / LYTENAVA™ (bevacizumab-vikg) as the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD, DME and BRVO. If ONS-5010 is approved, Outlook Therapeutics expects to commercialize it as the first and only FDA-approved ophthalmic formulation of bevacizumab for use in treating retinal diseases in the United States, United Kingdom, Europe, Japan, Greater China and other markets. Outlook Therapeutics expects to submit ONS-5010 with the U.S. FDA as a new BLA under the PHSA 351(a) regulatory pathway during the first calendar quarter of 2022.
SOURCE:
https://careers-outlooktherapeutics.icims.com/jobs/search?ss=1
BioLexis is doing Tax Planning to minimize tax payments selling OTLK shares in a Buyout.
With the agreement among BioLexis, GMS Ventures & Investments (GMS V&I), and certain GMS affiliates on April 21, 2022.
GMS V&I (Venture and Investments) has taken direct ownership of all the shares of Outlook Therapeutics, ...
....that were indirectly owned by GMS Holdings through BioLexis and certain GMS affiliates.
GMS Venture & Investments is a company incorporated under the laws of Cayman Island.
I think they expect to receive a lot of money from the sale of OTLK shares in a Buyout, and are already doing tax planning to minimize tax payments.
Caymen Island is Tax haven for the ultra wealthy and where big business deals happen. They are definitely prepping for something to happen within this year. Count on it !
(See more information about OTLK at r/OTLK_Investors)
OTLK - BioLexis Reorganization Results in GMS Holdings as Largest Shareholder in Outlook Therapeutics ("BUYOUT ON THE WAY?")
April 22, 2022
SINGAPORE and ISELIN, N.J., April 22, 2022 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a pre-commercial biopharmaceutical company working to develop and launch the first FDA-approved ophthalmic formulation of bevacizumab for use in retinal indications, and BioLexis Pte Ltd. (“BioLexis”), a strategic shareholder in Outlook Therapeutics, today announced that BioLexis is being reorganized.
The BioLexis reorganization, which does not entail any changes in the indirect ownership of Outlook Therapeutics, provides GMS Holdings with increased flexibility to support the future growth of Outlook Therapeutics as its largest shareholder.
Pursuant to an agreement among BioLexis, GMS Ventures & Investments (“GMS V&I”), and certain of GMS V&I’s affiliates (GMS V&I and its affiliates, “GMS Holdings”), on April 21, 2022, GMS V&I has taken direct ownership of all of the shares of Outlook Therapeutics that were indirectly owned by GMS Holdings through BioLexis.
As the next step in the reorganization, GMS Holdings will cease to be a shareholder in BioLexis and BioLexis will be renamed “Tenshi Healthcare Pte Limited” (or such other name as may be approved by the regulatory authorities in Singapore).
GMS Holdings does not have an economic interest in, or voting rights with respect to, the shares of Outlook Therapeutics that are held by BioLexis. BioLexis directly holds the shares beneficially owned by the minority shareholder in BioLexis, Tenshi Life Sciences Private Limited and Tenshi Life Sciences Pte Limited.
Since the initial investment by BioLexis in 2017, Outlook Therapeutics has undergone a significant transformation and has successfully completed three clinical trials which recently culminated in a BLA submission to the U.S. FDA on March 30, 2022. As the largest investor, GMS Holdings actively supported Outlook Therapeutics by leading and participating in multiple capital raises to support the Outlook Therapeutics growth strategy.
“The submission of a Biologics License Application (BLA) for ONS-5010 / LYTENAVA ™ (bevacizumab-vikg) with FDA is a significant milestone to achieve and places Outlook Therapeutics on a path to potential marketing approval for a very promising therapy,” said Faisal Sukhtian, Executive Director of GMS Holdings and a member of the Board of Directors of BioLexis. “With this milestone accomplished, the shareholders of BioLexis have fully realized their intended objectives for the joint venture.
This reorganization will see the existing partners translate their joint ownership positions in Outlook Therapeutics into direct stakes.”
“We appreciate the longstanding support we have received from BioLexis and look forward to executing on our priorities to create value for all shareholders,” added Russell Trenary, President and CEO of Outlook Therapeutics.
In connection with the reorganization, Outlook Therapeutics and GMS Holdings entered into an Amended and Restated Investor Rights Agreement, which replaces the previous Investor Rights Agreement among Outlook Therapeutics, BioLexis and GMS V&I.
BioLexis no longer has any rights under the Amended and Restated Investor Rights Agreement.
SOURCE: https://ir.outlooktherapeutics.com/node/10356/pdf
Many thanks H2R,
I also wish you good profits on your investments, I hope you include OTLK.
I invite you to join r/OTLK_Investors, it was created by me, and I am the moderator.
You can see there a lot of information and opinions about OTLK.
I wish you a Happy Easter.
All the best for you.
Pedro Felgueiras
OTLK - Interview about confidence in the FDA approval process for BLA
“Usually to pass FDA you want to have a 95% confidence level that you drug is working…we have in OTLK 99.5% confidence level.”
See the interview with C. Russell Trenary III (OTLK-President & Chief Executive Officer) on Proactive in the link below
Thanks H2R
All the best also for your investments.
Best Regards
Pedro Felgueiras
HILZINGER KURT J. report that he bought more 47.160 OTLK shares, now he have 245.409 OTLK shares.
Another INSIDER BUY in OTLK!
HILZINGER KURT J. , report on SEC FORM 4 that he bought more 47.160 OTLK shares, now he have 245.409 OTLK shares.
On February 24, 2022 bought 41,160 OTLK shares at $1,46
On February 28, 2022 bought 6,000 OTLK shares at $1,60
SOURCE: https://ir.outlooktherapeutics.com/static-files/25d8b5d5-77c5-445a-9c66-334215960ccd
"OTLK It's not a Trade, it's a Project. Becoming a Millionaire takes work!"
also:
"THE BIG MONEY IS NOT IN THE BUYING AND THE SELLING, BUT IN THE WAITING"
See more information about OTLK at r/OTLK_Investors
OTLK I believe Price above $2 end of February 2022!
Today OTLK was GREEN and Price UP +7,1%, was a good day for OTLK!
Also After Market the OTLK Price continues to go UP.
The Form 25 is regarding OTLKW Series A Warrants going Away on is exercisable date Feb 18, 2022. (See FROM 25 SEC).
Source: https://ir.outlooktherapeutics.com/static-files/bb95874b-d49f-4a22-847b-e733a25d2932
Can be one more step to the Buyout!
(See more information about OTLK at r/OTLK_Investors)
OTLK is looking for Director of Financial Planning and Analysis
"(Maybe hire someone else from AmerisourceBergen to plan and organize the Buyout)"
Opportunity and Summary of Position:
Director of Financial Planning and Analysis will oversee the budget and finances of the company.
Reporting Relationships:
The Director of Financial Planning and Analysis at Outlook Therapeutics’ reports to the Financial Controller.
Position Responsibilities:• Forecasting, budgeting and long-range planning.• Decision support on initiatives and investments.• Performance analysis and management reporting.• Identify and drive profitability and cash flow improvements.• Preparing revenue projections and forecasting expenditure.• Link revenue forecasts with margin expectations.• Develop mid and long-range strategic plans.• Ensure investment strategies support cost savings.• Evaluate resource investments and provide recommendations.• Track business case results with closed loop to forecast and budget• Produce KPIs with scorecards for each cost category.• Perform analysis on all operating metrics and KPIs.• Results v budget with variance analysis and explanation. Evaluation of gap closure initiatives with tracking• Support Business unit and product profitability. Business Unit and Product margin views• Synergy and integration tracking. Drive process and organizational efficiency initiatives• Creates and implements business plans, projections, budgets, and other single and multi-year analysis projects.• Collaborates with other departments and senior leadership to establish an effective budget for the organization.• Provides relevant financial information to executive management team.• Communicates with management on behalf of the Chief Financial Officer.• Collaborates with the Chief Financial Officer and Financial Controller and assists as needed for all matters related to the organization’s financial, planning, and budget programs.• Performs other related duties as assigned.
**Candidate Qualifications:**The company is seeking an individual with the following qualifications and who is willing to make a long-term commitment to the organization:
Education/Certificationo Bachelor’s degree in accounting, finance or business required; MBA and/or CPA preferred.o Bachelor’s degree with 10-15+ years of experience in Finance and Business management roles, preferably FP&A.o Strong presentation, interpersonal, and written skills.o Leadership experience in people management, program management and a strong track record of effectiveness in execution, time management, and influencing to deliver objectives.o Strong execution orientation and ability to inspire action.
Qualifications and Skillso Exceptional verbal and written communication skills.o Excellent organizational skills and attention to detail.o Ability to prioritize and delegate tasks.o Ability to analyze and evaluate budgets and financial models.o Ability to create and present ideas and budgets in a variety of formats.o Ability to maintain confidential records.o Proficient with Microsoft Office Suite or related software as needed to create and analyze budgets.
CompensationAn attractive compensation package will be offered to the successful candidate. It will include a competitive base salary and incentive bonus. A benefits package customary to the position will also be provided including 401k match, medical and dental.Outlook Therapeutics is an equal opportunity employer.
Interested applicants can send resumes to: HR@outlooktherapeutics.com
Source: https://outlooktherapeutics.com/director-fpa/
OTLK - Corporate Presentation February 2022
Everything goes as planned!
Source: https://ir.outlooktherapeutics.com/static-files/b4e4a969-af03-4f17-9680-882c1c84239d
Top 10 Hedge Funds Holding OTLK
In total we count 55 hedge funds holding OTLK as of their latest 13F filing, but among those we've sorted out just the top ten hedge funds holding OTLK by largest position size, and presented them here in slideshow format.
#1. BlackRock Inc.
#2. Vanguard Group Inc
#3. LVW Advisors LLC
#4. State Street Corp
#5. Geode Capital Management LLC
#6. Millennium Management LLC
#7. Northern Trust Corp
#8. Stelac Advisory Services LLC
#9. Two Sigma Advisers LP
#10. Nuveen Asset Management LLC
See more information about OTLK at r/OTLK_Investors
Source: By Holdings Channel Staff, updated Tuesday, January 25, 2:24 AM
$OTLK Buyout?
Where will NOVARTIS spend the $20.7B from Roche stake sale?
Novartis pharma division’s chief financial officer Mukul Mehta highlighted eye and respiratory diseases as possible areas for bolt-on deals, Welford noted in a Wednesday note after talking to the executive.
Novartis is getting a huge influx of cash from selling its 20-year stake in Roche, triggering speculation about where the Swiss pharma will spend the money $20,7B
What will it be next NOVARTIS M&A move? ...OTLK?
Another large acquisition could be next, with a familiar face now reportedly on the shopping list.
Buy on rumors, sell on news!
See more information about OTLK at r/OTLK_Investors
Oncology belongs to a different division at Novartis.
OTLK - The pre-offer of a Buyout has started? (More opinions I read regarding a OTLK Buyout)
"I Think the pre-offer buying of OTLK Buyout has started!"
A buyout will be based on the value to the buyer, not the share price.
A low share price means a potential buyer may try to buy up as many shares pre-offer as possible.
Let's say you offer $30/share.
If you accumulated 10MM shares before the offer was made, you saved $300MM dollars.
If someone beats your offer, you still sell those 10MM shares for a profit.
I think this is why we are seeing bear raids and FUD accounts.
I think the pre-offer buying has started.
I expect an offer to be announced around the time the FDA accepts the BLA.
Any offer will be based on the buyer's valuation.
Whoever has the highest valuation will make the highest offer.
Share price won't matter a lick.
So a $30/share offer is reasonable, if a buyer thinks the value is there.
This is why I keep saying that none of us has enough information to know what the offer will be.
But I think it will be $8-$12MMM . Or less. Probably not more. I would be amazed if it's less than $5MMM
For more information about OTLK, see at r/OTLK_Investors